Teleflex (TFX) Upgrades the Arrow ErgoPack Complete System
Teleflex TFX recently announced the release of the Arrow ErgoPack Complete Kit with Hemodialysis and Large Bore catheters in the United States. In the expanded kit configuration, clinicians can select between Arrowg+ard Blue Hemodialysis and Large Bore lines, with a variety of French sizes, lumens and lengths.
The latest development is intended to streamline the insertion workflow for clinicians and provide more options to suit their needs. This is likely to bolster “Arrow” brand innovations under Teleflex’s Vascular Access product group.
Enhancements in Detail
The Arrow ErgoPack Complete System expansion includes a variety of clinician-inspired updates. These include the Arrow GlideWheel Advancer, which provides tactile feedback and finer control, while the Nitinol wire included in the System is kink-resistant compared to stainless steel. The Transducer cover supports the guidelines for ultrasound insertion.
Image Source: Zacks Investment Research
Each kit contains one pre-filled sterile saline syringe per lumen along with an additional ChloraPrep Skin Preparation applicator. It also has the option of 3M Tegaderm CHG I.V. Securement Dressing or 3M Tegaderm I.V. Advanced Securement Dressing with BioPatch Protective Disk.
More in the News
Maximal Barrier kits, such as the Arrow ErgoPack Complete System, provide clinicians with the necessary components they need for their Acute Hemodialysis and Large Bore insertions. The system’s unique combination of CVC insertion components is packaged in an ergonomic, efficient top-down, left-to-right configuration.
The design of the intuitive configuration optimizes their workflow and helps central line inserters meet the recommendations of critical third-party independent guidelines for reducing CLABSI. These are Centers for Disease Control and Prevention (“CDC”) Category 1A & 1B recommendations, Society for Hospital Epidemiology of America (“SHEA”) Guidelines, the Infusion Nursing Society (“INS”) Standards of Practice and the Occupational Health and Safety Administration (“OSHA”) Bloodborne Pathogens Standard.
Per a representative at the company, these benefits, along with the protection from Arrowg+ard Blue Catheters, help clinicians fight against central line-associated bloodstream infections, protecting their patients and improving their procedures.
Industry Prospects
Per a Research report, the global vascular access device market is expected to witness a CAGR of nearly 6.5% through the 2022-2027 period.
Recent Developments
Earlier this month, TFX received FDA clearance for the QuikClot Control+ Hemostatic Device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a sternotomy. This allows clinicians to use the device to control all bleeding in cardiac surgical procedures.
In June 2023, Teleflex announced a partnership with Shenzhen Insighters Medical Technology Co., Ltd. as the exclusive U.S. distributor of the Insighters Video Laryngoscope system. It is designed to inspect the upper glottic airway and facilitate endotracheal intubation.
Price Performance
In the past six months, TFX shares have decreased 9.3% compared with the industry’s decline of 3%.
Zacks Rank and Key Picks
Teleflex currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Haemonetics HAE, Quanterix QTRX and SiBone SIBN, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics’stock has risen 11.2% in the past year. Earnings estimates for Haemoneticshave increased from $3.56 to $3.74 in 2023 and $3.96 to $4.07 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have increased 174.2% in the past year against the industry’s decline of 5.3%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s 2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 23.7% in the past year against the industry’s fall of 5.1%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Teleflex Incorporated (TFX) : Free Stock Analysis Report
Quanterix Corporation (QTRX) : Free Stock Analysis Report
SiBone (SIBN) : Free Stock Analysis Report
